We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
RXi Pharmaceuticals unveiled positive safety and efficacy results in an early-phase study of its antifibrotic agent RXI-109 in patients with advanced neovascular age-related macular degeneration.......